Research Committee of the Netherlands Cancer Registry. Incidence of cancer in the Netherlands 1999/2000. 2003; 1.0.
Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678–701.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792.
Lynch HT, Albano WA, Danes BS, et al. Genetic predisposition to breast cancer. Cancer 1984; 53: 612–622.
Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med 1997; 336: 1401–1408.
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265–271.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318–2324.
Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362–371.
Kaas R, Kroger R, Hendriks JH, et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur Radiol 2004; 14: 1647–1653.
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 1999; 340: 77–84.
Grann VR, Jacobson JS, Whang W, et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 2000; 6: 13–20.
Evans D, Lalloo F, Shenton A, Boggis C, Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001; 358: 889–890.
Vasen HF, Haites NE, Evans DG, et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34: 1922–1926.
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909–919.
Stomper PC, D'Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1353 women 25–79 years old. Am J Roentgenol 1996; 167: 1261–1265.
Lehman CD, White E, Peacock S, Drucker MJ, Urban N. Effect of age and breast density on screening mammograms with false-positive findings. Am J Roentgenol 1999; 173: 1651–1655.
Zonderland HM, Coerkamp EG, Hermans J, van de Vijver MJ, van Voorthuisen AE. Diagnosis of breast cancer: contribution of US as an adjunct to mammography. Radiology 1999; 213: 413–422.
Shaw de Paredes E, Marsteller LP, Eden BV. Breast cancers in women 35 years of age and younger: mammographic findings. Radiology 1990; 177: 117–119.
Morrow M. Identification and management of the woman at increased risk for breast cancer development. Breast Cancer Res Treat 1994; 31: 53–60.
Peer PG, Verbeek AL, Straatman H, Hendriks JH, Holland R. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat 1996; 38: 153–160.
Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63: 53–60.
Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267–279.
Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102: 91–95.
Feig SA. Assessment of radiation risk from screening mammography. Cancer 1996; 77: 818–822.
Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology 1997; 202: 413–420.
Viehweg P, Paprosch I, Strassinopoulou M, Heywang-Kobrunner SH. Contrast-enhanced magnetic resonance imaging of the breast: interpretation guidelines. Top Magn Reson Imag 1998; 9: 17–43.
Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J Am Med Assoc 2004; 292: 1317–1325.
Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: 115–124.
Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10: 199–204.
Brasch RC, Weinmann HJ, Wesbey GE. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. Am J Roentgenol 1984; 142: 625–630.
Strich G, Hagan PL, Gerber KH, Slutsky RA. Tissue distribution and magnetic resonance spin lattice relaxation effects of gadolinium-DTPA. Radiology 1985; 154: 723–726.
Kelcz F, Santyr G. Gadolinium-enhanced breast MRI. Crit Rev Diagn Imag 1995; 36: 287–338.
Obdeijn IM, Kuijpers TJ, van Dijk P, Wiggers T, Oudkerk M. MR lesion detection in a breast cancer population. J Magn Reson Imag 1996; 6: 849–854.
Bone B, Pentek Z, Perbeck L, Veress B. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol 1997; 38: 489–496.
Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997; 24: 94–108.
Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 1997; 44: 179–182.
Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 1997; 205: 437–440.
Gilles R, Zafrani B, Guinebretiere JM, et al. Ductal carcinoma in situ: MR imaging–histopathologic correlation. Radiology 1995; 196: 415–419.
Westerhof JP, Fischer U, Moritz JD, Oestmann JW. MR imaging of mammographically detected clustered microcalcifications: is there any value? Radiology 1998; 207: 675–681.
American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS® Atlas), 2003.
Brett J, Austoker J, Ong G. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. J Public Health Med 1998; 20: 396–403.
Gilhuijs KG, Deurloo EE, Muller SH, Peterse JL, Schultze Kool LJ. Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions initial results. Radiology 2002; 225: 907–916.
Deurloo EE, Muller SH, Peterse JL, Besnard APE, Gilhuijs KGA. Clinically and mammographically occult breast lesions at MR imaging: potential impact of computerized assessment on clinical reading. Radiology 2005 (in press).
Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl J Med 2004; 351: 427–437.
Liberman L. Breast cancer screening with MRI – what are the data for patients at high risk? New Engl J Med 2004; 351: 497–500.
Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. J Am Med Assoc 2004; 292: 1368–1370.